精品国产一区二区桃色

Member News

Honors for Baserga, Matunis and Tate

ASBMB Today Staff
Sept. 9, 2024

Baserga elected to AAA&S

Susan Baserga has been elected to the American Academy of Arts & Sciences, Biochemistry, Biophysics and Molecular Biology section. She is being recognized for her excellent scientific achievements and will be inducted this month during a ceremony in Cambridge, Massachusetts.

Susan Baserga

Baserga is a professor of molecular biophysics and biochemistry, of genetics and of therapeutic radiology at the Yale University School of Medicine. Her  focuses on understanding how ribosomes are made in eukaryotic cells. Specifically, they study the pathogenesis of ribosomopathies, diseases caused by abnormalities in ribosome biogenesis that can induce cancer.

Baserga is a fellow of the National Academy of Inventors and a member of the National Academy of Medicine. She has received the Connecticut Technology Council Women of Innovation in Research and Leadership Award, the Charles W. Bohmfalk Prize for basic science teaching at the Yale School of Medicine and the 精品国产一区二区桃色’s William C. Rose Award for outstanding research and commitment to training young scientists. She is a 2023 ASBMB fellow and chairs the society’s Women in Biochemistry and Molecular Biology Committee.

“We honor these artists, scholars, scientists and leaders in the public, non-profit and private sectors for their accomplishments and for the curiosity, creativity and courage required to reach new heights,” David Oxtoby, AAA&S President, said in a . “We invite these exceptional individuals to join in the Academy’s work to address serious challenges and advance the common good.”

Matunis honored for JBC research

Michael Matunis won the 2024 Shikani/El-Hibri Prize for Discovery and Innovation from the Johns Hopkins Bloomberg School of Public Health. Fuad El-Hibri, a businessperson in the biotech industry, and Alan Shikani, an otolaryngologist and graduate of Johns Hopkins, created this prize to reward innovations in basic science that could lead to public health solutions.

portrait of Michael Matunis
Michael Matunis

Matunis is a professor of biochemistry and molecular biology at Johns Hopkins. His focuses on a class of small ubiquitin-like modifier proteins, or SUMOs. The prize recognized his lab’s recent discovery of a . They showed that SUMO1 is required for the turnover of a particular type of misfolded protein in yeast as well as humans. The winning research was published last year in the 精品国产一区二区桃色’s . Matunis is a fellow of the American Society for Cell Biology and the American Association for the Advancement of Science.

“This insight into how SUMO1 works could lead to new treatments for diseases caused by protein misfolding like cancer, heart disease and Alzheimer's,” , a professor and chair of biochemistry and molecular Biology at Johns Hopkins, said.

Tate wins RSC prize

Ed Tate and a team of researchers won the 2024 Chemistry Biology Interface Horizon Prize: Rita and John Cornforth Award from the Royal Society of Chemistry. The Cornforths were groundbreaking research partners, and John Cornforth won the Nobel Prize in chemistry in 1975 for their work on the stereochemistry of enzyme-catalyzed reactions.

Ed Tate

Other Horizon Prize-winning team members hail from the University of Liverpool, Liverpool School of Tropical Medicine, University of Bonn, AstraZeneca and Eisai Co., Ltd. Their collaborative drug discovery research led to the first synthetic drug candidate for tropical diseases caused collectively by roundworms and the bacteria Wolbachia.

Tate is a professor and the chair of chemical biology at Imperial College London. His research interests lie at the intersection of organic chemistry, biology and medicine. Tate’s  uses medicinal chemistry and chemical synthesis to find therapeutics for infectious diseases, cancer and more. He also founded Myricx Bio, a biotech company focused on the discovery and development of selective cytotoxic payloads for antibody drug conjugates, based on inhibitors of N-myristoyltransferases, for the treatment of cancer.

A fellow of both the RSC and the Royal Society of Biology, Tate has received the Wain Medal Lecture and Prize, the President and Rector's Award for Excellence in Research Supervision, the Norman Heatley Award, the Cancer Research U.K. Program Foundation Award, the Sir David Cooksey Translation Prize and the RSC Corday–Morgan Prize. 


 

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
ASBMB Today Staff

This article was written by a member or members of the ASBMB Today staff.

Get the latest from ASBMB Today

Enter your email address, and we鈥檒l send you a weekly email with recent articles, interviews and more.

Latest in People

People highlights or most popular articles

In memoriam: Michael J. Chamberlin
In Memoriam

In memoriam: Michael J. Chamberlin

Dec. 15, 2025

He discovered RNA polymerase and was an ASBMB member for nearly 60 years.

Building the blueprint to block HIV
Profile

Building the blueprint to block HIV

Dec. 11, 2025

Wesley Sundquist will present his work on the HIV capsid and revolutionary drug, Lenacapavir, at the ASBMB Annual Meeting, March 7鈥10, in Maryland.

In memoriam: Alan G. Goodridge
In Memoriam

In memoriam: Alan G. Goodridge

Dec. 9, 2025

He made pioneering discoveries on lipid metabolism and was an ASBMB member since 1971.

Alrubaye wins research and teaching awards
Member News

Alrubaye wins research and teaching awards

Dec. 8, 2025

He was honored at the NACTA 2025 conference for the Educator Award and at the U of A State and National Awards reception for the Faculty Gold Medal.

Designing life鈥檚 building blocks with AI
Profile

Designing life鈥檚 building blocks with AI

Dec. 2, 2025

Tanja Kortemme, a professor at the University of California, San Francisco, will discuss her research using computational biology to engineer proteins at the 2026 ASBMB Annual Meeting.

Jordahl named Gilliam Fellow
Member News

Jordahl named Gilliam Fellow

Dec. 1, 2025

He will receive three years of funding to support his thesis research.